en · de · es
creatine-notes.peptides8425.com › Faq › Identity And Research Context — Deep Dive

Identity And Research Context — Deep Dive

By Editorial Desk · published 2026-07-01 · last reviewed 2026-08-01 · Faq

This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

Identity and Research Context

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Research and Regulatory Status

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Aod-9604 at a glance

PropertyValueNotes
Common nameAOD-9604Development code used in scientific literature.
Chemical classSynthetic peptideFragment of human growth hormone.
Amino acid length16 residuesMatches hGH region 176-191.
AppearanceWhite to off-white powderTypical lyophilized peptide solid.
SolubilitySoluble in waterDissolves in aqueous media; exact behavior depends on salt form.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Related pages on this site

Regulation and Detection Context

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.

Identity and Molecular Context

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Notes from published material

is the density of reagent ions in absence of reactant molecules in the buffer gas, k is the reaction rate constant and t is the average time the ions need to pass the reaction region. With a PTR-MS instrument the number of product and of reagent ions can be measured, the reaction rate constant can be found in literature for most substances and the reaction time can be derived from the set instrument parameters. Therefore, the absolute concentration of trace constituents

A vacuum flask (also known as a Dewar flask, Dewar bottle or thermos) is an insulating storage vessel that slows the speed at which its contents change in temperature. It greatly lengthens the time over which its contents remain hotter or cooler than the flask's surroundings by trying to be as adiabatic as possible. Invented by James Dewar in 1892, the vacuum flask consists of two flasks, placed one within the other and joined at the neck. The gap between the two flasks is partially evacuated of air, creating a near-vacuum which significantly reduces heat transfer by conduction or convection. When used to hold cold liquids, this also virtually eliminates condensation on the outside of the flask. Vacuum flasks are used domestically to keep contents inside hot or cold for extended periods of time. They are also used for thermal cooking. Vacuum flasks are also used for many purposes in industry.

== Water activity == The water activity, aw, in a fish is defined as the ratio of the water vapour pressure in the flesh of the fish to the vapour pressure of pure water at the same temperature and pressure. It ranges between 0 and 1, and is a parameter that measures how available the water is in the flesh of the fish. Available water is necessary for the microbial and enzymatic reactions involved in spoilage. There are a number of techniques that have been or are used to tie up the available water or remove it by reducing the aw. Traditionally, techniques such as drying, salting and smoking have been used, and have been used for thousands of years. These techniques can be very simple, for example, by using solar drying. In more recent times, freeze-drying, water binding humectants, and fully automated equipment with temperature and humidity control have been added. Often a combination of these techniques is used.

This will typically be 22 kilometres (14 miles) wide, but could be more (if a state has chosen to claim a territorial sea of less than 22 kilometres), or less, if it would otherwise overlap another state's contiguous zone. However, unlike the territorial sea, there is no standard rule for resolving such conflicts, and the states in question must negotiate their own compromise. America invoked a contiguous zone out to 44 kilometres from the baseline on 29 September 1999. Exclusive economic zone: An exclusive economic zone extends from the baseline to a maximum of 370 kilometres (230 miles). A coastal nation has control of all economic resources within its exclusive economic zone, including fishing, mining, oil exploration, and any pollution of those resources. However, it cannot prohibit passage or loitering above, on, or under the surface of the sea that complies with the laws and regulations adopted by the coastal State in accordance with the provisions of the UN Convention, within that portion of its exclusive economic zone beyond its territorial sea. The only authority a state has over its EEZ is, therefore, its ability to regulate the extraction or spoliation of resources contained therein, and border-control measures implemented to this effect focus on the suppression of unauthorised commercial activity. Vessels not complying with a state's maritime policies may be subject to ship arrest and enforcement action by the state's authorities.

Sources: en.wikipedia.org

Further detail

The Kingdom of Hungary collapsed, and the Ottomans occupied parts of Banat and Crișana in 1541. Transylvania and Maramureș, along with the rest of Banat and Crișana, developed into a new state under Ottoman suzerainty, the Principality of Transylvania. The Reformation, initiated in Germany by Martin Luther in 1517, encouraged the spread of Protestantism across the region; by 1568, the Edict of Torda formally granted local communities the right to choose their own preachers, sanctioning the existence of four "received" religions (Catholicism, Lutheranism, Calvinism, and Unitarianism. The Romanians' Orthodox faith remained only tolerated, although they made up more than one-third of the population, according to 17th-century estimates. In June 1609, Gabriel Báthory freed the Romanian Orthodox clergy from both taxation and service demands. The princes of Transylvania, Wallachia, and Moldavia joined the Holy League against the Ottoman Empire in 1594. The Wallachian prince, Michael the Brave, united the three principalities under his rule in May 1600. The neighbouring powers forced him to abdicate in September, but he became a symbol of the unification of the Romanian lands in the 19th century. Although the rulers of the three principalities continued to pay tribute to the Ottomans, the most talented princes—Gabriel Bethlen of Transylvania, Matei Basarab of Wallachia, and Vasile Lupu of Moldavia—strengthened their autonomy.

Many of the organisms, such as Charnia, found in Mistaken Point, were not like any organisms seen today. They had distinct bodies, however were lacking a head and digestive regions. Rather their body was organized in a very simple, fractal-like branching pattern. Every element of the body was finely branched and grew by repetitive branching. This allowed the organism to have a large surface area and maximize nutrient absorption without needing a mouth and digestive system. However, there was minimal genetic information and therefore did not have the requirements that would have allowed them to evolve more efficient feeding techniques. This means they were probably outcompeted by other organisms, and thus became extinct. The organisms found in the Ediacaran Hills in Southern Australia displayed either radially symmetric body plans or, one organism, Spriggina, displayed the first bilateral symmetry. The Ediacaran Hills are thought to have once had a shallow reef where more light could penetrate the bottom of the ocean floor. This allowed for more diversity of organisms. The organisms found here resemble relatives of the cnidarians, mollusks or annelids.

=== Spinal leak === The vast majority of CSF leaks are spinal. Spinal leaks occur when one or more holes form in the dura along the spinal cord. There are three types of spontaneous spinal CSF leaks. A spinal leak typically causes spontaneous intracranial hypotension.

Sources: en.wikipedia.org

Background from the literature

Some applications for ambient ionization include environmental applications as well as clinical applications. In these techniques, ions form in an ion source outside the mass spectrometer. Sampling becomes easy as the samples don't need previous separation nor preparation. Some examples of ambient ionization techniques are Direct Analysis in Real Time (DART), DESI, SESI, LAESI, atmospheric pressure chemical ionization (APCI), desorption atmospheric-pressure chemical ionization (DAPCI), Soft Ionization by Chemical Reaction in Transfer (SICRT) and desorption atmospheric pressure photoionization DAPPI among others.

== Further reading == Appanna, Varun P.; Auger, Christopher; Thomas, Sean C.; Omri, Abdelwahab (13 June 2014). "Fumarate metabolism and ATP production in Pseudomonas fluorescens exposed to nitrosative stress". Antonie van Leeuwenhoek. 106 (3): 431–438. doi:10.1007/s10482-014-0211-7. PMID 24923559. S2CID 1124142. Cabrefiga, J.; Frances, J.; Montesinos, E.; Bonaterra, A. (1 October 2014). "Improvement of a dry formulation of Pseudomonas fluorescens EPS62e for fire blight disease biocontrol by combination of culture osmoadaptation with a freeze-drying lyoprotectant". Journal of Applied Microbiology. 117 (4): 1122–1131. doi:10.1111/jam.12582. PMID 24947806.

== Early life and education == Delibegovic is from Tuzla in Bosnia and Herzegovina. She grew up during the Bosnian War, which forced her family apart. In the early nineties, she moved to Scotland and finished her secondary school education at George Heriot's School in Edinburgh. Delibegovic studied pharmacology at the University of Edinburgh. In the final year of her undergraduate degree Delibegovic moved to Essex, where she did her undergraduate final year project at GlaxoSmithKline on novel anti-diabetes drugs. She completed her doctoral research with Prof Dame Patricia Cohen at the University of Dundee Medical Research Council Protein Phosphorylation Unit. Here she studied the way that enzymes such as protein phosphatase 1 influenced diabetes development. She was supported by the Royal Society studentship. She has said that she was interested in diabetes because of family history and prevalence of Type 2 diabetes in Bosnia and Herzegovina. During her doctoral research, Delibegovic worked closely with pharmaceutical companies to translate her research to the read world. In 2003 she was awarded the American Heart Association personal fellowship to study the role of PTPN1 in glucose homeostasis at the Harvard Medical School in Boston, USA. She spent four years in Boston, working with Prof Benjamin Neel on mouse models of insulin resistance.

The journey across the United States began on 15 July 1988. On the journey he slept in bushes beneath the World Trade Center, camped outside Kennedy Airport in a tent, then headed west. On Staten Island he collapsed from heat exhaustion at 105 degrees Fahrenheit. In Utah the temperatures went down to minus 30 Fahrenheit. Carrying a tent and a backpack, with no backup, he walked alone to Niagara Falls, through Ontario in Canada, to Detroit, between the Great Lakes, across the Great Plains, through the Rockies in winter, to Yellowstone National Park, then south to the Grand Canyon, on to Las Vegas, through Death Valley and then snowshoed over the Sierras to reach San Francisco. In Death Valley, down to his last $13, Skinner found $200 in the desert, and he had $1 left when he crossed the Sierras to reach Yosemite Valley. The total distance he walked from New York City to San Francisco, was 4,952 miles (7,969 km). On the journey he visited 70 hospices and appeared on television, radio and in newspapers to encourage support for hospices across the U.S. and Canada. The mayor of San Francisco, Art Agnos, proclaimed 21 March 1989, "Colin Skinner Day," in recognition of the attention he brought to the work of hospices with AIDS patients in the city. Returning to Britain after this walk, he obtained a job as a research assistant in Chemical Pathology at the Middlesex Hospital and went on to obtain a PhD in Molecular Biology at University College London.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Is AOD-9604 the same as human growth hormone?

No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.

Why is it called hGH fragment 176-191?

The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Network